Skip to main content
. 2018 Feb 14;26(4):1082–1092. doi: 10.1016/j.ymthe.2018.02.008

Figure 4.

Figure 4

Histology Amelioration of TA Treated with AAV shDnm2

(A) TA sections of WT or Mtm1KO mice treated with AAV-shRNA ctrl or shDnm2 (C or I) were stained with H&E and SDH to visualize fiber size, shape, nuclei positioning, and mitochondrial oxidative activity. Arrows show mislocalized nuclei or aggregated mitochondria (scale bars: 50 μm). (B) TA myofiber area was calculated on 300–400 fibers per sample (n = 5 mice/group). (C) Fiber size distribution of WT or Mtm1KO TAs according to size groups. Affected Mtm1KO TAs have more small fibers and less medium-size or large fibers. (D) Percentage of fibers with mislocalized nuclei was determined in 1,000 fibers (n = 5–6 mice/group). (E) Percentage of fibers with abnormal mitochondrial distribution was determined in 1,000 fibers (n = 5 mice/group). ***p < 0.001 versus WT TA treated with shRNA ctrl. $$$p < 0.01 Mtm1KO treated with AAV-shDnm2 versus Mtm1KO treated with AAV-shRNA ctrl (ANOVA test).